BioCentury | Mar 13, 2020
Tools & Techniques

How to feed the machine: lessons from an AI antibiotics study

The recent AI-based discovery of broad-spectrum antibiotic candidates highlights the potential of new machine learning methods to find compounds humans might otherwise miss, but ups the ante on the quality and diversity of input data...
BioCentury | May 28, 2019
Distillery Therapeutics

Dual activation of JNK1 and JNK2 for STK11-deficient lung cancer

DISEASE CATEGORY: Cancer INDICATION: Lung cancer Patient sample, cell culture and mouse studies suggest dual activation of JNK1 and JNK2 could help treat STK11-deficient squamous cell carcinoma (SCC) of the lung. In patients, low tumor...
BioCentury | Feb 2, 2018
Clinical News

Auris reports additional Phase III data of brimapitide for hearing loss

Auris Medical Holding AG (NASDAQ:EARS) reported additional data from the Phase III HEALOS trial evaluating single intratympanic doses of 0.4 and 0.8 mg/mL brimapitide (AM-111, D-JNKI-1, XG-102) gel in 256 patients with severe to profound...
BioCentury | Jan 3, 2018
Preclinical News

CYLD expression could slow progression of NASH

In a paper published in Nature Medicine , researchers at Wuhan University and Weill Cornell Medicine found that increasing expression of the deubiquitinating enzyme cylindromatosis turban tumor syndrome (CYLD) reversed progression of non-alcoholic steatohepatitis (NASH) in...
BioCentury | Dec 1, 2017
Clinical News

Auris misses in Phase III hearing loss trial

Auris Medical Holding AG (NASDAQ:EARS) stock fell 49% Nov. 28 after the company said brimapitide (AM-111) missed the primary endpoint in the Phase III HEALOS trial. Neither tested dose of intratympanic brimapitide gel significantly improved...
BioCentury | Nov 28, 2017
Clinical News

Auris' lead candidate misses in Phase III hearing loss trial

Auris Medical Holding AG (NASDAQ:EARS) fell $0.40 (49%) to $0.42 Tuesday after it said brimapitide (AM-111) missed the primary endpoint in the Phase III HEALOS trial. Neither tested dose of intratympanic brimapitide gel significantly improved...
BioCentury | Oct 28, 2017
Product Development

Chinks in the armor

Even with slowing revenues tied largely to a single product and a dearth of launches, Wall Street darling Celgene Corp. had been on an extended tear, growing its share price in excess of 300% since...
BioCentury | Oct 5, 2017
Translation in Brief

Chronic neuroprotection

Two studies by Genentech have shown DLK inhibition is neuroprotective in two chronic neurodegenerative diseases and suggest the target may play a broad role in driving neurodegeneration, regardless of the underlying cause. MAP kinase kinase...
BioCentury | Jun 15, 2017
Tools & Techniques

Breaking the barrier

A three-way deal between Amgen Inc. , Feldan Therapeutics Inc. and Elasmogen Ltd. is the latest cause for optimism that technologies are finally converging to enable the generation of cell-penetrating biologics. The biotechs join a small...
BioCentury | Jun 2, 2017
Product Development

Ears wide open

Based on unmet need alone, hearing loss should have been every bit as attractive to investors and drug developers as ophthalmic diseases, which entered a renaissance in the mid-2000s resulting in a multibillion-dollar market for...
Items per page:
1 - 10 of 119